{
    "root": "2f9bc7ba-3217-7a04-e063-6394a90a8330",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pioglitazone",
    "value": "20250305",
    "ingredients": [
        {
            "name": "CARBOXYMETHYLCELLULOSE CALCIUM",
            "code": "UTY7PDF93L"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "PIOGLITAZONE HYDROCHLORIDE",
            "code": "JQT35NPK6C"
        }
    ],
    "indications": "monotherapy combination therapy pioglitazone tablets indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus multiple settings [ ( 14 ) ] . important limitations pioglitazone tablets exert antihyperglycemic effect presence endogenous insulin . pioglitazone tablets used treat type 1 diabetes diabetic ketoacidosis , would effective settings . caution patients liver disease [ ( 5.3 ) ] .",
    "contraindications": "initiate pioglitazone tablets 15 mg 30 mg daily . limit initial dose 15 mg daily patients nyha class ii heart failure . ( 2.1 ) inadequate glycemic control , dose increased 15 mg increments maximum 45 mg daily . ( 2.1 ) obtain liver tests starting pioglitazone tablets . abnormal , caution treating pioglitazone tablets , investigate probable cause , treat ( possible ) follow appropriately . monitoring liver tests pioglitazone tablets recommended patients without liver disease . ( 5.3 )",
    "warningsAndPrecautions": "pioglitazone available 30 mg tablets follows : pioglitazone tablets usp , 30 mg white off-white , round , flat faced , beveled edge uncoated tablets , debossed \u201c 32 \u201d one side \u201c h \u201d side . ndc : 70518-2129-00 packaging : 90 1 bottle plastic storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . keep container tightly closed , protect light , moisture humidity . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "initiation patients established nyha class iii iv heart failure [ boxed warning ] . patients known hypersensitivity pioglitazone component pioglitazone tablets .",
    "indications_original": "Monotherapy and Combination Therapy \n   \n                        \n                     Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings\n \n  [see\n  \n   Clinical Studies (14)]\n \n  . \n  \n                     \n                     Important Limitations of Use \n   \n                     \n                       Pioglitazone tablets exert its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. \n  \n                       Use caution in patients with liver disease\n \n  [see\n  \n   Warnings and Precautions (5.3)]\n \n  .",
    "contraindications_original": "Initiate pioglitazone tablets at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II heart failure. (2.1) If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. (2.1) Obtain liver tests before starting pioglitazone tablets. If abnormal, use caution when treating with pioglitazone tablets, investigate the probable cause, treat (if possible) and follow appropriately. Monitoring liver tests while on pioglitazone tablets are not recommended in patients without liver disease. (5.3)",
    "warningsAndPrecautions_original": "Pioglitazone\u00a0is available in 30\u00a0mg tablets as follows:\n                  Pioglitazone Tablets USP, 30 mg\u00a0are white to off-white, round, flat faced, beveled edge uncoated tablets, debossed with \u201c32\u201d on one side and \u201cH\u201d on other side.\n                  \n                  NDC: 70518-2129-00\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Storage\n                  \n                  Store at\u00a020\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Keep container tightly closed, and protect from light, moisture and humidity.\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Initiation in patients with established NYHA Class III or IV heart failure\n  \n   [see\n   \n    Boxed Warning].\n  \n   \n                     \n                     \u00a0Use in patients with known hypersensitivity to pioglitazone or any other component of pioglitazone tablets."
}